Veracyte, Inc. raised revenue guidance for the full year 2023. For the period, the company raised total revenue guidance to $352 million to $354 million, representing year-over-year growth of approximately 19%, and an improvement compared to prior guidance of $342 million to $350 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.31 USD | -0.87% | -0.72% | -29.81% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.81% | 1.48B | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 383M | |
+13.32% | 332M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023